Ask AI
ProCE Banner Activity

Experts Discuss Contemporary Treatment of Multiple Myeloma

Clinical Thought

In this commentary, expert faculty respond to healthcare professional questions from a live webinar and share their perspectives on optimal treatment of patients with newly diagnosed and relapsed/refractory multiple myeloma.

Released: March 05, 2025

Expiration: March 04, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner
ProCE Banner

Supporters

This educational activity is supported by an independent medical education grant from GSK and an educational grant from Sanofi.

Sanofi

Disclosure

Primary Author

Jens Hillengass, MD, PhD

Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Jens Hillengass, MD, PhD: consultant/advisor/speaker: Angitia, BeiGene, Janssen, Prothena, Regeneron, Sebia.

Carol Ann Huff, MD

Professor of Oncology and Medicine
Multiple Myeloma Program
Johns Hopkins University
Medical Director
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Carol Ann Huff, MD: consultant/advisor/speaker: Bristol Myers Squibb, Janssen Biotech, Legend Biotechnologies, Prothena, Sanofi Aventis; researcher: Prothena.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD: consultant: AbbVie, Amgen, ArcellX, Beigene, BMS, Carsgen, ,GSK, Janssen, K36, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Takeda, CVS Caremark, BD Biosciences; clinical trial support to institution: AbbVie, Amgen, Astra Zeneca, BMS, Carsgen, GSK, Gracell Bio, Janssen, Oricell, Roche-Genentech, Sanofi, Takeda, Telogenomics.